| NCT ID | NCT06464445 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Université de Sherbrooke |
| Condition | Neuromodulation |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-08-01 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Repetitive TMS (rTMS) is a well-established method for modulating brain activity. Through successive stimulations in the form of magnetic fields, it is possible to modify the sensitivity of neurons in the brain, also known as cortical excitability. Cortical excitability is important for the induction of brain plasticity, the ability of the brain to reorganize itself and form new connections in response to stimuli. A particular class of rTMS, intermittent theta burst TMS (iTBS), is commonly used to modulate cortical excitability and induce plasticity for therapeutic purposes, notably for treatment-resistant depression. Different iTBS stimulation parameters can be used to induce plasticity. This study will focus on two parameters, namely, the form and duration of the electromagnetic stimulation. The shape of the electromagnetic pulse refers to how the electromagnetic wave is configured over time, while the duration is simply the period during which this electromagnetic pulse remains active. These parameters are expected to influence the effectiveness of iTBS in modulating cortical activity but remain little studied. The main aim of this study will be to compare the effectiveness of different stimulation parameters in the induction of plasticity, which will then make it possible to improve the rTMS protocols used for treatment-resistant depression.
Eligibility Criteria
Inclusion Criteria: * Be between 18 and 35 years old * Be of right manual dominance * In good health Exclusion Criteria: * Have an implant or pacemaker, * Having tinnitus, * Have a history of fainting, * Have already had an epileptic seizure or have a family history of epilepsy, * Have a known neurological disease, * Be under psychotropic medication, * Have suffered from substance abuse or dependence in the last 6 months, * Have a neurostimulator, * Have a splinter or metallic implant in the head or the rest of the body, * Have a cochlear implant, * Have an automated injection system implanted (insulin pump), * Have a transdermal patch, * Have tattoos in the area to be studied, * Be pregnant or breastfeeding,
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06464445 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 35 Years, studying Neuromodulation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06464445 currently recruiting?
Yes, NCT06464445 is actively recruiting participants. Contact the research team at Samantha.cote@usherbrooke.ca for enrollment information.
Where is the NCT06464445 trial being conducted?
This trial is being conducted at Sherbrooke, Canada.
Who is sponsoring the NCT06464445 clinical trial?
NCT06464445 is sponsored by Université de Sherbrooke. The trial plans to enroll 30 participants.